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Abstract
Background: While racial/ethnic survival disparities have been described in pediat-
ric oncology, the impact of income has not been extensively explored. We analyzed 
how public insurance influences 5-year overall survival (OS) in young patients with 
sarcomas.
Methods: The University of California San Francisco Cancer Registry was used 
to identify patients aged 0-39 diagnosed with bone or soft tissue sarcomas between 
2000 and 2015. Low-income patients were defined as those with no insurance or 
Medicaid, a means-tested form of public insurance. Survival curves were computed 
using the Kaplan-Meier method and compared using log-rank tests and Cox models. 
Causal mediation was used to assess whether the association between public insur-
ance and mortality is mediated by metastatic disease.
Results: Of 1106 patients, 39% patients were classified as low-income. Low-income 
patients were more likely to be racial/ethnic minorities and to present with metastatic 
disease (OR 1.96, 95% CI 1.35-2.86). Low-income patients had significantly worse 
OS (61% vs 71%). Age at diagnosis and extent of disease at diagnosis were also 
independent predictors of OS. When stratified by extent of disease, low-income pa-
tients consistently had significantly worse OS (localized: 78% vs 84%, regional: 64% 
vs 73%, metastatic: 23% vs 30%, respectively). Mediation analysis indicated that 
metastatic disease at diagnosis mediated 15% of the effect of public insurance on OS.
Conclusions: Low-income patients with bone and soft tissue sarcomas had decreased 
OS regardless of disease stage at presentation. The mechanism by which insurance 
status impacts survival requires additional investigation, but may be through reduced 
access to care.
K E Y W O R D S
AYA, cancer disparities, health insurance, pediatrics, sarcoma
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1 |  BACKGROUND
Racial and ethnic survival disparities have been described 
for many pediatric malignancies.1-3 These differences are 
suspected to be due, in part, to differences in tumor biol-
ogy, as inferior outcomes have been demonstrated in certain 
ethnic groups independent of socioeconomic status (SES).4 
However, tumor biology alone cannot explain these survival 
disparities. In studies of adult cancer, poverty has been shown 
to contribute to survival disparities through diminished ac-
cess to health care, resulting in delays in diagnosis and treat-
ment and leading to presentation with advanced disease that 
is more difficult to cure.5-10 The impact of SES has not been 
extensively explored in the pediatric cancer setting.
While sarcomas are very rare among adult malignancies, 
they represent 12%-15% of all pediatric tumors, with approx-
imately 1700 children and young adults diagnosed yearly in 
the United States.11 They comprise a heterogeneous group of 
tumors, categorized according to their tissue of origin (soft 
tissue or bone), and are treated with a combination of sur-
gery and/or radiotherapy to achieve local control, and che-
motherapy directed toward occult or overt metastatic disease. 
Despite improvements in outcomes over the last four decades 
due to use of multimodal therapy—an approach informed by 
the work of multi-institutional cooperative groups—approx-
imately one-third of patients, nonetheless, succumb to their 
disease.12-14
To assess whether SES affects pediatric sarcoma out-
comes, we evaluated low-income public health insurance as 
a proxy for income. Medicaid is a state and federally funded 
program which provides health insurance to low-income 
patients; coverage is available under state law to eligible 
low-income individuals or families.15,16 We analyzed how 
low-income public health insurance influenced overall sur-
vival (OS) in children, adolescents, and young adults diag-
nosed with bone and soft tissue sarcomas.
2 |  METHODS
We performed a retrospective analysis of data from the 
University of California San Francisco Cancer Registry. 
Patients were included if they were diagnosed with bone or 
soft tissue sarcoma between 2000 and 2015 and if they were 
aged between 0 and 39 years at the time of their diagnosis. 
We identified 1123 potentially eligible records. Of these, six 
were excluded because they were incorrectly categorized as 
sarcoma and 11 were excluded because insurance status was 
unknown. A total of 1106 records were available for com-
plete analysis.
Our two primary outcomes of interest were OS and stage 
of disease at diagnosis. Stage of disease was coded as local-
ized, regional, or metastatic according to American Joint 
Committee on Cancer (AJCC) staging assessments. The pri-
mary exposure of interest was health insurance type, defined 
in the University of California San Francisco Cancer Registry 
as the primary insurance carrier or method of payment at 
diagnosis.
In the UCSF Cancer Registry, data on patient demograph-
ics, primary tumor site, tumor morphology and stage at diag-
nosis, and follow-up for vital status are routinely collected. 
The UCSF Cancer Registry classifies race based on informa-
tion from the medical record. Hispanic ethnicity was deter-
mined using stated ethnicity in the medical record, national 
origin on the death certificate, spoken language, place of 
birth, and surname. For this analysis, race and ethnicity were 
considered a compound variable; patients were grouped into 
five different groups: white non-Hispanic, white Hispanic, 
Asian non-Hispanic (Asian), African American non-His-
panic (African American), and American Indian. Bone and 
soft tissue sarcomas encompass a diverse array of histologic 
subtypes, with heterogeneity in prognosis and treatment; 
we performed a subgroup analysis of patients with the four 
most common histologic subtypes. Treatment data, includ-
ing method of local control, were inconsistently collected. 
Thus, treatment modality variables were not included in the 
analysis.
2.1 | Statistical analyses
We extracted raw data and imported into Stata 15 (Stata-
Corp, College Station, TX) for analysis. We calculated de-
scriptive statistics for patient and tumor characteristics, and 
evaluated differences between groups using Chi-square tests. 
We defined OS based on all-cause mortality from diagno-
sis, with survival times calculated as the number of months 
between date of diagnosis and death. We assigned censor-
ing times for surviving individuals using the date of last 
follow-up, or 31 December 2015. We summarized OS using 
Kaplan-Meier estimates17 with 95% confidence intervals. 
We evaluated between-group differences using the log-rank 
test. We generated Kaplan-Meier plots for all patients and 
according to the extent of disease at presentation (localized, 
regional, or metastatic). The median follow-up time for the 
analyzed cohort was 59 months. We truncated Kaplan-Meier 
plots at 200 months. However, all available data were used in 
estimates of distributions and group comparisons.
We used univariate and multivariable Cox regression18 
to evaluate predictors of OS; covariates included sex, age 
(<15 years, 15-29 years, or >29 years of age), race/ethnic-
ity, and disease stage at diagnosis. We performed subgroup 
analysis of patients with the four most common histologic 
subtypes, and adjusted for covariates listed above, as well as 
histology. Covariates were chosen a priori based on the liter-
ature and on the potential for confounding. We used hazard 
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ratios (HR) and 95% confidence intervals to evaluate these 
covariates as predictors of OS. The proportional hazards 
assumption was evaluated using Schoenfeld residuals after 
fitting all Cox models. To evaluate whether the impact of 
insurance was greater among patients with more advanced 
disease, we performed a test of interaction on the multiplica-
tive scale between low-income public insurance and stage of 
disease at diagnosis.
To evaluate the potential impact of excluding patients 
missing stage of disease at diagnosis, we used chained mul-
tiple imputation techniques to fill in missing values based on 
modeled relationships with other analysis variables.19 This 
approach to missing data has been validated by a number of 
simulation studies20,21 and has been employed in studies uti-
lizing population-based cancer registry data.22 Stage of dis-
ease at diagnosis had 17% missing data, and was the only 
imputed variable.
In order to evaluate the hypothesis that the association 
between public insurance status and mortality is mediated 
by the presence of metastatic disease, we used methods for 
causal mediation analysis.23 This approach is similar to the 
standard Baron and Kenny method for linear regression mod-
els,24 but is appropriate for nonlinear models for binary and 
survival outcomes, and incorporates a more flexible means 
for control of possible confounding variables.
As a prerequisite for mediation, we considered whether 
patients with public insurance were more likely to present 
with advanced stage disease. Logistic regression was used to 
assess the relationship between insurance and disease stage 
at diagnosis. Once confirmed, we included public insurance 
status as the primary predictor variable, and the presence of 
metastatic disease as the mediator, both represented as binary 
indicators. These variables were included in a parametric 
survival regression model for the OS outcome, which was 
assumed to follow a Weibull distribution, with surviving 
individuals treated as censored. The relationship between 
public insurance status and the presence of metastases (the 
mediator) was modeled with logistic regression. Both mod-
els adjusted for age at diagnosis, white (vs non-white) race, 
and gender (male vs female) as possible confounding factors. 
Results were summarized as the estimated percentage of the 
effect of having public insurance on OS mediated by the pres-
ence of metastatic disease with a 95% confidence interval.
All statistical comparisons were two-sided and signifi-
cance was achieved at level P < .05.
3 |  RESULTS
3.1 | Patient and tumor characteristics
The study population included 1106 patients. Insurance type 
was coded as uninsured (n = 8), any low-income public insur-
ance (Total [n = 420]: Medicaid [n = 318], Medicaid through 
managed care [n = 53], county funded [n = 20], Indian/pub-
lic health service [n = 14], Medicare with Medicaid supple-
ment [n = 15]), or private insurance (Total [n = 678]: HMO 
[n = 104], PPO [n = 136], managed care [n = 415], Tricare 
[n = 6], Medicare [n = 11], fee-for-service [n = 3], military 
coverage [n = 3]). Given the small number of uninsured pa-
tients, these patients were included in the low-income public 
insurance group.
Of the total population, 420 patients (38.7%) had public 
insurance and eight patients (0.7%) had no insurance. The 
demographic characteristics of the study population accord-
ing to insurance status are shown in Table 1. Significant dif-
ferences in insurance were noted according to race/ethnicity 
with the public insurance group containing a higher propor-
tion of Hispanic and African American patients. No statisti-





Age (y) 21.2 (±10.75) 22.4 (±10.78) .06
Sex
Female 163 (38.1%) 298 (44.0%) .075
Male 264 (61.7%) 380 (56.1%)  
Race/ethnicity
White, non-Hispanic 154 (36%) 455 (67.1) <.001
White, Hispanic 188 (43.9%) 98 (14.5%)  
African American 30 (7.0%) 24 (3.5%)  
Asian/Pacific Islander 52 (12.2%) 98 (14.5%)  
American Indian 4 (0.9%) 3 (0.4%)  
T A B L E  1  Demographic 
characteristics of cohort by insurance type
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regard to age, sex, or primary site. The tumor characteristics 
of the study population according to insurance status are 
shown in Table 2. A greater proportion of low-income public 
insurance patients presented with regional or metastatic dis-
ease than those patients with private insurance (P < .001). 
There was a higher proportion of bone tumors in the low-in-
come public insurance group compared to the private insur-
ance group (P  =  .011). The histologic subtypes that were 
represented and their relative proportions in the sample are 
shown in Table S1. The histologic subtypes with the highest 
representation in the sample were osteosarcoma (n = 232, 
20.98%), rhabdomyosarcoma (n = 132, 11.9%), Ewing sar-
coma (n = 113, 10.2%), and chondrosarcoma (n = 70, 6.3%).
3.2 | Differences in overall survival 
by insurance
The 5- and 10-year OS rates for the entire cohort were 66% and 
58%, respectively. There was a statistically significant differ-
ence in OS by insurance status (HR 1.26, 95% CI 1.21-1.78, 
P = .0001, Figure 1); patients with low-income public insur-
ance had significantly worse 5- and 10-year OS compared to 
those with private insurance (61% vs 71%, 49% vs 63%, re-
spectively, P = .0001). When stratified by localized, regional, 
or metastatic disease, those with low-income public insurance 
had worse 5-year OS compared to those with private insurance 
across all three strata: localized (78% vs 84%), regional (64% vs 
73%), and metastatic (23% vs 30%, P < .0001 for each compari-
son). These differences in survival persisted at 10 years: local-
ized (60% vs 77%), regional (54% vs 63%), and metastatic (19% 
vs 30%, P < .0001 for each comparison) (Figure 2). There were 
no significant survival differences between the bone and soft 
tissue sarcoma groups (HR 0.92, 95% CI: 0.76-1.13, P = .44) 
irrespective of insurance status.
3.3 | Univariate and multivariable analyses
Race/ethnicity was not significantly associated with OS 
in univariate analysis. Significant univariate predictors 
of OS included male sex (HR = 1.26, 95% CI: 1.04-1.55, 
P  =  .021), age 15-29 at diagnosis (HR  =  1.34, 95% CI 
1.06-1.70, P  =  .015), regional disease at diagnosis (HR 
1.50, 95% CI 1.15-1.95, P  =  .002), metastatic disease at 
diagnosis (HR 3.95, 95% CI 3.05-5.10, P  <  .001), and 
low-income public insurance (HR 1.46, 95% CI 1.20-1.78, 
P < .001). In multivariable analysis, the association of sur-
vival with male sex resolved when controlling for other 
factors. However, age 15-29 at diagnosis (HR = 1.38, 95% 
CI 1.08-1.75, P = .009), regional disease at diagnosis (HR 
1.47, 95% CI 1.13-1.93, P  =  .004), metastatic disease at 
diagnosis (HR = 3.79, 95% CI 2.90-4.94, P <  .001), and 
low-income public insurance (HR  =  1.27, 95% CI 1.02-
1.57, P =  .032) remained significant independent predic-
tors of OS (Table 3).
In subgroup analysis of patients with the four most com-
mon histologic subtypes (osteosarcoma, rhabdomyosarcoma, 
Ewing sarcoma, chondrosarcoma, n = 547), histologic sub-
type (osteosarcoma: HR 2.91, 95% CI 1.49-5.67, P = .002; 
rhabdomyosarcoma: HR 3.34, 95% CI 1.67-6.69, P = .001), 
age at diagnosis (age 15-29: HR 1.66, 95% CI 1.23-2.23, 
P = .001; age >29: HR 2.87, 95% CI 1.82-4.51, P < .001), 
metastatic disease at diagnosis (HR 3.8, 95% CI 2.57-5.63, 
P < .001), and low-income public insurance (HR 1.38, 95% 
CI 1.02-1.86, P = .035) were significant predictors of OS in 
multivariable analysis (Table S2).
Patients with low-income public insurance were more 
likely than those with private insurance to present with 
metastatic disease (OR 1.96, 95% CI 1.35-2.86, P < .001) 
after accounting for sex, age at diagnosis, and race/ethnic-
ity. We did not find evidence of a statistically significant in-
teraction between having low-income public insurance and 
stage of disease at diagnosis (Wald test P = .60). Mediation 
analysis indicates that metastatic disease at diagnosis me-
diates 15.3% (95% CI: 5%-34%) of the association between 
public insurance and OS. Corresponding results incorpo-
rating imputed data for missing disease stage at diagnosis 
were similar.
4 |  DISCUSSION
Our analyses demonstrate that pediatric, adolescent, and 
young adult bone and soft tissue sarcoma patients with 
public insurance had inferior OS compared to patients 
with private insurance. This survival disparity was noted 
irrespective of stage of disease at diagnosis. While pa-
tients with public insurance were more likely to present 
with metastatic disease at diagnosis, public insurance was 








Bone 181 (42.3%) 235 (34.7%) .011
Soft tissue 247 (57.7%) 443 (65.3%)  
Primary site
Non-pelvis 362 (84.5%) 570 (84.1%) .82
Pelvis 66 (15.4%) 108 (15.9%)  
Stage at diagnosis
Localized 154 (36.0%) 308 (45.4%) <.001
Regional 115 (26.9%) 164 (24.2%)  
Metastatic 91 (21.3%) 85 (12.5%)  
Unknown 68 (15.9%) 121 (17.8%)  
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independently associated with diminished survival, even 
when controlling for sex, race/ethnicity, age, and stage 
of disease, as well as when stratified by stage of disease. 
In subgroup analysis, using the four most common histo-
logic subtypes represented in the sample, public insurance 
remained independently associated with inferior survival 
even when controlled for histologic subtype, as well as sex, 
race/ethnicity, age, and stage of disease.
In this study, we used public insurance such as Medicaid 
as a proxy to identify low-income patients, as coverage is 
only available under California state law to individuals or 
families whose income is near the threshold for poverty. 
Studies of adult cancer have implicated SES in outcome dis-
parities in a host of cancers, particularly those where avail-
ability of screening allows for early detection such as breast 
and colon cancer.25,26 Other authors have noted worse cancer 
outcomes in Medicaid recipients27,28 and have theorized that 
while access to screening and early detection may be a con-
tributor, the disparities are more broadly attributable to social 
determinants of health,29 such as poverty itself. Patients who 
are enrolled in Medicaid often face a myriad of obstacles to 
medical care such as lack of transportation,30-32 lack of social 
support,33,34 lower health literacy,35-37 and lack of funds for 
deductibles and prescriptions.38 Additionally, Medicaid pa-
tients may be vulnerable to physiologic stressors, such food 
and housing insecurity39-41 and toxic stress, which affect their 
overall health status.42 However, our cancer registry lacks in-
formation related to individual socioeconomic characteristics 
such as income, education, and employment, which would 
assist in interrogating the association between public insur-
ance and survival further.
Adolescents and young adults (AYA) aged 15-29 in our study 
had inferior survival compared with younger children and older 
adults, which is consistent with the current literature.43,44 The 
role of insurance in AYA cancer disparities has been explored by 
several authors, given the historical underinsurance of this age 
group.45 Previous studies have found that among young adults 
with cancer, private insurance coverage was associated with de-
creased likelihood of metastatic disease and death5,6; however, 
patients with public insurance were handled differently in each 
analysis. In explaining these inferior outcomes among the AYA 
population, researchers have postulated that lack of insurance 
F I G U R E  1  Kaplan-Meier curves of overall survival by low-
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F I G U R E  2  Kaplan-Meier curves of overall survival by low-
income insurance status among patients with (A) localized,  
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could result in diagnostic delays and subsequent presentation 
with later stage (and more difficult to treat) disease. In fact, 
Martin et al found that among young adults, health insurance 
type was significantly associated with lagtimes between onset of 
cancer symptoms and definitive diagnosis, and that longer lag-
times were associated with more advanced stage disease.9 The 
Affordable Care Act, which allows young adults to remain on 
their parents' insurance plan until the age of 26 years, has the 
potential to improve access to medical care in this vulnerable 
group.51 While expansion of insurance access will likely affect 
population health positively, concurrent measures directed to-
ward poverty eradication would likely have synergistic benefits 
for cancer outcomes.
Another possible mechanism for the inferior survival in 
those with public insurance could relate to receipt of insuffi-
cient treatment. Specifically, achievement of local control is 
of paramount importance in sarcoma management; however, 
the optimal mode of local control (surgical resection vs ra-
diation) remains unclear.47,48 Previous studies have demon-
strated racial disparities in receipt of surgical treatment for 
adult malignancies49,50; in particular, a study of pediatric and 
young adult patients with chest wall sarcoma demonstrated 
racial disparities in receipt of surgical resection with asso-
ciated inferior survival.51 Unfortunately, we lacked adequate 
data regarding treatment, such as method of local control, to 
ascertain whether there were treatment differences between 
insurance groups that could explain the noted disparities. 
Additionally, inferior access to care for complications of ther-
apy and potentially increased risk of complications related to 
host factors (such as general nutritional status and the pres-
ence of medical comorbidities) could also influence survival.
Our data support the hypothesis that presentation with 
later stage disease partially mediates the relationship between 
low-income public insurance and death, as there was a clear 
association between public insurance and advanced stage dis-
ease. Furthermore, adjustment for stage of disease decreased 
the hazard ratio for the relationship between public insurance 
and survival. However, stage only partially explains this dis-
parity, and cannot explain the inferior survival outcomes we 
noted among patients with localized or regional disease. It is 
possible that those patients with localized and regional disease 
received suboptimal treatment or disease surveillance, or were 
unable to adhere to recommended follow-up. In addition, our 
mediation analysis is vulnerable to unmeasured confounders, 
such as patient's primary language, education, and indicators 
of individual- and community-level poverty, introducing bias.
While sample size and quality of curated, structured regis-
try data are strengths of this study, several limitations should 
 
Univariate Multivariable
HR 95% CI P HR 95% CI P
Sex
Female Reference     Reference    
Male 1.26 1.04-1.55 .021 1.06 0.84-1.34 .59
Age at diagnosis
<15 Reference     Reference    
15-29 1.34 1.06-1.70 .015 1.38 1.08-1.75 .009
>29 1.00 0.78-1.28 .982 1.09 0.85-1.41 .50
Race/ethnicity




1.07 0.88-1.30 .473 0.96 0.78-1.19 .71
Stage
Local Reference     Reference    
Regional 1.50 1.15-1.95 .002 1.47 1.13-1.93 .004








1.46 1.20-1.78 <.001 1.27 1.02-1.57 .032
Bold text indicates a statistically significant difference with a P value less than .05.
T A B L E  3  Univariate and 
multivariable Cox proportional hazard 
models evaluating the hazard of survival for 
patients with bone and soft tissue sarcomas
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be mentioned. Within our data, the rate of uninsurance (<1% 
of total sample) is lower than what has been described in the 
literature,46 and may be explained by insurance enrollment at 
diagnosis. Moreover, insurance status is vulnerable to mis-
classification, as individuals may be retroactively enrolled on 
Medicaid at diagnosis. This misclassification may be differen-
tial if those with more advanced disease were more likely to be 
uninsured. This misclassification could suggest that an asso-
ciation exists between low-income public insurance and met-
astatic disease, when truly uninsurance was the driver. Prior 
studies have reported that uninsured patients have distinctly 
inferior outcomes compared with those with public or private 
insurance.5,10,52 Because public insurance has been handled 
differently by different authors, the existing literature is dif-
ficult to extrapolate; risks associated with discrete insurance 
types should be queried in future studies. Additionally, the 
lack of reliable treatment detail in our data makes a deeper un-
derstanding of the mechanism behind the association between 
public insurance and survival difficult to discern.
Our findings demonstrate that public insurance is a strong 
independent risk factor for advanced disease at diagnosis and 
inferior OS among pediatric, adolescent, and young adults 
with bone and soft tissue sarcoma. While the survival dis-
parity is partially mediated by advanced disease at diagno-
sis, other mechanisms likely explain the residual disparity. 
Additional studies to evaluate other mechanisms that underlie 
the survival disparity are essential in order to target interven-
tions to the appropriate contributing factors. In particular, the 
role of poverty in pediatric cancer disparities merits further 
investigation.
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